Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label cannabidiol adjunctive treatment for anorexia nervosa
ACTRN12622001306707Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in anorexia nervosa (AN), sponsored by University of Sydney. Primary endpoints: Safety and tolerability of cannabidiol and Feasibility. Started Apr 2023; status: completed.
02
Drugs
cannabidiol
03
Conditions
anorexia nervosa (AN)
Beyond the preview
Go deeper on ACTRN12622001306707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001306707.